This review summarises the role that reactive oxygen and nitrogen species play in demyelination, such as that occurring in the inflammatory demyelinating disorders multiple sclerosis and Guillain-Barré syndrome. The concentrations of reactive oxygen and nitrogen species (e.g. superoxide, nitric oxide and peroxynitrite) can increase dramatically under conditions such as inflammation, and this can overwhelm the inherent antioxidant defences within lesions. Such oxidative and/or nitrative stress can damage the lipids, proteins and nucleic acids of cells and mitochondria, potentially causing cell death. Oligodendrocytes are more sensitive to oxidative and nitrative stress in vitro than are astrocytes and microglia, seemingly due to a diminished capacity for antioxidant defence, and the presence of raised risk factors, including a high iron content. Oxidative and nitrative stress might therefore result in vivo in selective oligodendrocyte death, and thereby demyelination. The reactive species may also damage the myelin sheath, promoting its attack by macrophages. Damage can occur directly by lipid peroxidation, and indirectly by the activation of proteases and phospholipase A₂. Evidence for the existence of oxidative and nitrative stress within inflammatory demyelinating lesions includes the presence of both lipid and protein peroxides, and nitrotyrosine (a marker for peroxynitrite formation). The neurological deficit resulting from experimental autoimmune demyelinating disease has generally been reduced by trial therapies intended to diminish the concentration of reactive oxygen species. However, therapies aimed at diminishing reactive nitrogen species have had a more variable outcome, sometimes exacerbating disease.

Recent years have witnessed a burgeoning of interest in the role that reactive oxygen and nitrogen species (ROS and RNS) play in inflammation, and also in the role that inflammation plays in multiple sclerosis (MS). These interests have naturally focused attention on the potential role of ROS and RNS in demyelinating disease, the subject of this review.

Oxidative And Nitrative Stress

Cells within the nervous system are routinely exposed to low concentrations of potentially deleterious reactive oxygen and nitrogen species, but these normally pose little threat since cells possess an arsenal of defence and repair mechanisms. However, events such as inflammation can conspire to increase the production of these reactive species dramatically, and this may overwhelm the cell’s defences resulting in a condition known as oxidative and/or nitrative “stress”. Such stress may lead to changes in the properties of the cell’s constituent molecules, notably the lipids, proteins and nucleic acids. The ROS and RNS of primary concern are the superoxide anion (O₂⁻, hereafter called superoxide), nitric oxide (nitrogen monoxide, *NO*), peroxynitrite (ONOO⁻; a product of the combination of superoxide and nitric oxide), hydrogen peroxide (H₂O₂), and the hydroxyl radical (*OH*). Other potentially important species include singlet oxygen (¹O₂), nitrogen dioxide radical (NO₂⁻), nitrosonium (NO⁺) and nitronium (NO₂⁺).

* The dot signifies that the compound is a radical, namely a compound possessing one or more unpaired electrons, i.e. electrons that occupy an atomic or molecular orbit by themselves. This configuration can make the compound reactive. Superoxide and nitric oxide are both radicals, but they are not as reactive as some of their derivatives.
ions, the perhydroxyl radical (HO\textsubscript{2}•), and hypochlorous acid (HOCl), but since there is little direct evidence so far that these species play an important role in demyelination, they will not be discussed in this review. The reactions initiated by the reactive species include peroxidation of lipids, nitrosylation of thiol groups, nitration of tyrosine, and oxidation and deamination of nucleic acids. Reactions such as these may directly, or indirectly, result in demyelination. If this is correct, then novel therapies for demyelinating disorders may arise from the introduction of strategies aimed at modifying the production and fate of ROS and RNS. This review describes the evidence that ROS and RNS play a role in demyelination, the mechanisms believed to be involved, and observations made from trial therapies in demyelinating disorders.

Inherent Vulnerability Of The Nervous System To Oxidative Damage

The CNS is inherently vulnerable to damage mediated by ROS. First, it is very active in oxidative metabolism. Such activity results in a relatively high intracellular production of superoxide, since 2-5% of the oxygen consumed in mitochondrial electron transport is converted to superoxide. Superoxide is converted by the enzyme superoxide dismutase (SOD) to hydrogen peroxide and oxygen (98). Hydrogen peroxide is normally reduced to water by the action of catalase or glutathione peroxidase (with reduced glutathione as co-substrate), but in the presence of decompartmentalised transition metals such as iron and copper it can be converted to the highly toxic hydroxyl radical (98). This radical is so reactive that it has a diffusion radius of only approximately 0.3 nm before it interacts with another molecule (11). For comparison, the interlamellar spacing of myelin is approximately 10 nm. Second, the CNS has a very limited ability to conduct anaerobic glycolysis, and so it is unusually vulnerable to hypoxia. This is a concern since the production of superoxide by mitochondria increases dramatically in low oxygen concentrations (reviewed in (10)). Third, some cells in the CNS, notably oligodendrocytes, have relatively low levels of antioxidant defences combined with a high iron content and extensive elaborations of membranes. These features all predispose oligodendrocytes, in particular, to oxidative damage. Finally, myelin membrane is a preferential target of ROS (24) due to its composition and high lipid to protein ratio.

It has been proposed that the brain may be much more vulnerable to oxidative stress than the spinal cord or peripheral nerve (139). However, the levels of the antioxidant glutathione and glutathione related enzyme activities appear to be lower in peripheral nervous tissue than in the central nervous system, suggesting that this protective mechanism, at least, is less effective in the peripheral nervous system (188).

Cellular Oxidative Defence Mechanisms

Cells employ a range of defence mechanisms to protect themselves from oxidative and nitrative injury. The strategy includes mechanisms to limit the production of reactive species, to scavenge any radicals that are produced, to prevent the proliferation of secondary radicals in chain reactions, and to repair the damage that may nevertheless occur. This strategy is achieved by the presence of antioxidant enzymes such as SOD, glutathione peroxidase and catalase, and low molecular weight antioxidants such as glutathione and dietary vitamins C and E. There are two forms of SOD. Mn-SOD is located in mitochondria, and Cu/Zn-SOD is located within the cytosol. Both isofoms specifically catalyse the dismutation of superoxide to hydrogen peroxide and oxygen, thereby protecting cells from the formation of the more harmful peroxynitrite. Glutathione peroxidase is an important cytosolic selenium-containing enzyme which converts peroxides, notably hydrogen peroxide and lipid peroxides, to water and oxygen. The enzyme requires reduced glutathione as an electron donor. Catalase converts hydrogen peroxide in peroxisomes to water and oxygen. Glutathione is pivotal to oxidative defence and performs the non-specific reduction of many ROS and RNS. It can also reactivate some enzymes which have been inhibited by exposure to oxidants. Glutathione is found at high concentrations in cells, particularly in astrocytes (~5 mM) (230). Vitamin C (ascorbate) is another important, non-specific antioxidant, which accumulates in the CNS particularly in astrocytes (up to 10 mM) (208, 209). Vitamin C can regenerate glutathione and vitamin E from their radicals in vitro, returning them to the antioxidant pool. Vitamin E (α-tocopherol) is a lipid soluble antioxidant, and forms a primary defence against lipid peroxidation. It can break the chain reactions of lipid peroxidation by reducing peroxyl radicals. The chemical biology of ROS and RNS has been reviewed in detail elsewhere (98, 186, 249).

Other recent reviews of potential interest examine the neurobiology of *NO (259), the role of *NO in mitochondrial damage (19), the effects of oxidative stress on astrocytes (173), the role of astrocytes in antioxidant defence (245), and the role of microglia in brain damage (151).

The Role Of Nitric Oxide In Demyelination
**NO has important physiological roles in the regulation of vascular tone, in intra- and inter-cellular communication, and in the destruction of microbes and tumour cells (for review see (226)). It is an important inflammatory mediator which also appears to exert significant effects in inflammatory demyelinating diseases.

**Elementary Chemistry of Nitric Oxide.** *NO is produced from L-arginine by a family of homodimeric enzymes, termed nitric oxide synthases (NOS), which require several co-substrates and co-factors, including oxygen, and NADPH. The family is made up of three members, nNOS (for “neuronal” NOS; also termed type I NOS), eNOS (for “endothelial”; also termed type II) and iNOS (for “immunological”, “inflammatory” or, most commonly, “inducible”; also termed type II) which are the products of separate genes on different chromosomes. Two forms, eNOS and nNOS, are expressed constitutively in endothelial cells and in some neurons respectively, and have collectively been termed cNOS. The inducible form, iNOS, differs from cNOS in two important ways. First, it produces relatively large amounts of *NO compared to cNOS, and second, it is effectively independent of Ca++ (for review see (151)).

*NO itself is not thought to be highly toxic at the concentrations formed in vivo. However *NO reacts rapidly with some molecules, particularly transition metals and other free radicals, and these reactions can lead to the formation of more damaging species (12). *NO has a short half-life (~1 second) in tissues. The chemistry of *NO and its derivatives is complex (reviewed in (11, 12, 14, 59)). Notably, *NO combines with superoxide to form the potent oxidising and nitrating agent, peroxynitrite. The rate constant for this reaction is sufficiently high that *NO out-competes SOD for superoxide (110). However, the relatively high concentration of SOD in the cell usually means that intracellular superoxide concentrations are kept sufficiently low that peroxynitrite formation is normally minimal. Under some conditions, however, such as during the oxidative burst, excess superoxide is produced and then extracellular peroxynitrite formation can be substantial (for review see (12)). Peroxynitrite is very reactive, and has a short half-life (milliseconds) in tissues. There is evidence that reaction of peroxynitrite in the presence of carbon dioxide enhances its nitrating properties. In fact, it is now believed that many of the deleterious effects ascribed to *NO in reality be due to peroxynitrite and the agents derived from it (including peroxynitrous acid, hydroxyl radicals and nitrogen dioxide radicals, and the nitronium ion). Therefore, reference to “*NO” in this review should not be taken to exclude its metabolic derivatives (i.e. peroxynitrite etc.).

**The Production Of Nitric Oxide In The Nervous System In Response To Inflammation.** The induction of iNOS, or the production of substantial amounts of *NO, has been reported in astrocytes (102, 206), microglia (18, 47, 264), a subset of oligodendrocytes (148), Schwann cells (82), and cerebral endothelium (26, 202). In addition, iNOS induction has been widely reported in macrophages and other cells which can invade the nervous system and participate in inflammatory reactions. Typically, the induction of iNOS is achieved experimentally by stimulation of cells with bacterial cell wall lipopolysaccharide (LPS), and/or the use of pro-inflammatory cytokines such as interferon-γ (IFNγ). However, CSF from 34% (13/38) of MS patients has been found to promote *NO production in mixed cultures of rat oligodendrocytes, microglia and astrocytes, vs. only 10% (2/20) of CSF samples from controls. Increasing *NO concentrations were accompanied by a proportion-}

control of Nitric Oxide Production. Most studies in this field suggest that the control of iNOS expression occurs predominantly at the transcriptional level and involves a number of transcription factors, including nuclear factor kappa-B (for review see (151)). Differences in transcription factor expression and the differential presence of consensus sequences are likely to be related to observed differences in species and tissue expression of iNOS. Post-transcriptional control of iNOS also occurs. For example, in mouse macrophages,
transforming growth factor-β (TGF-β) reduces iNOS activity by destabilising iNOS mRNA, reducing translation and increasing the degradation of iNOS (238).

The up-regulation of •NO production in glia using LPS, or LPS+IFNγ, has been shown to involve mitogen-activated protein (MAP) kinase cascades. Specific inhibition of either of two MAP kinases (extracellular signal-regulated kinase (ERK) or p38 kinase) reduces both the expression of iNOS and the production of •NO in primary cultures of rat glia, while inhibition of both kinases leads to almost complete inhibition (13).

The immune response encompasses a number of chemical interactions which regulate •NO production. For example, there is evidence that some eicosanoids can down-regulate •NO production. Addition of exogenous prostaglandin E2 (PGE2) to rat microglial cells down-regulates iNOS by increasing cAMP levels (152), and inhibition of cyclooxygenase increases •NO production in activated human astrocytes (116). Paradoxically, however, inhibition of cyclooxygenase in rat microglia decreases iNOS expression (152). These findings indicate that products of the arachidonic acid cascade may have both positive and negative regulatory effects on •NO production. •NO also participates in its own regulation. In activated astrocytes, the addition of •NO trapping agents increases the transcription of iNOS, indicating that •NO provides direct negative feedback on the enzyme responsible for its generation (170). An important “sink” for the removal of •NO is the vasculature, since •NO readily diffuses through tissue and reacts with oxyhaemoglobin to form methaemoglobin.

Cytokines also have a significant effect on iNOS expression and •NO production. In general, the pro-inflammatory cytokines such as interleukin-1α (IL-1α) (236), IL-1β (138, 207), IFNγ (207) and tumour necrosis factor-α (TNFα) (155) induce, or increase, the production of •NO in glia. The cytokines can act synergistically: for example, neither IFNγ nor TNFα cause significant •NO production by cultured astrocytes, but the combination of cytokines elicits a strong response (223). Glia can themselves synthesise cytokines which in turn lead to further up-regulation of iNOS. For example, the release of TNFα from astrocytes can cause the expression of iNOS in the cerebral endothelium (202). There is also recent evidence that TNFα and •NO may mutually provoke the production of the other in vitro (223). Anti-inflammatory cytokines such as IL-4 (207), IL-10 (207) and TGF-β1 (TGF-β1) (237) decrease the production of •NO in activated rodent glia in culture. Reports of similar suppression in human astrocytes vary. Liu et al. (138) found no inhibition of iNOS or •NO production, while Hu et al (108) found that all three cytokines acted as potent inhibitors of pro-inflammatory cytokine-induced •NO production in cultured human fetal astrocytes. IFNβ, which primarily exhibits anti-inflammatory properties, reduces •NO production in an astrocytoma cell line (90) and in primary astrocyte cultures (109). In some cases, the inhibitory action of these cytokines is mediated by blocking the production of pro-inflammatory cytokines (168). Thus the control of iNOS by cytokines involves both positive and negative interactions.

•NO production by phagocytes can be affected by exposure to myelin. Phagocytosis of rat myelin by rat macrophages in vitro leads to an increased production of •NO, and this effect can be enhanced by opsonizing the myelin with anti-myelin antibodies (157). The effect of phagocytosis is not limited to myelin, since activated microglia also produce more •NO after phagocytosing certain bacteria and latex beads (53).

There is also evidence that cells can modulate their expression of their oxidative and nitrative defence mechanisms, either in response to the challenge of oxidative and nitrative stress, or even in anticipation of such challenge. For example, cultured microglial cells respond to a LPS challenge by the induction of enzymes which produce high, antimicrobial concentrations of •NO. However, since the microglial cell may itself be impaired by such •NO concentrations, it appears first to render itself resistant to the effects of •NO: these measures are instituted in response to even low LPS concentrations (222). Furthermore, and presumably in an effort to avoid the toxicity of peroxynitrite, it appears that cells which can produce both superoxide and •NO tend to stagger their production so that both radicals are not produced at the same time. In part this may be achieved by the inhibition by •NO of the factors involved in superoxide production, and in part by the fact that the agents which stimulate •NO production typically do not also stimulate superoxide production (see (44) for discussion). However, it seems likely that this ingenious protection will be compromised in areas of inflammation, populated as they are by different types of cell presumably sometimes at different stages of activation. If so, then peroxynitrite formation may be anticipated in inflammatory lesions within the nervous system, and, indeed, there is evidence for this in MS lesions (see nitrotyrosine labelling under “MS” below).

Evidence For The Involvement Of Nitric Oxide In Demyelination. The diversity of interactions between
the host of inflammatory mediators make it difficult to establish a direct and causal link between *NO and demyelination. For example, even if the inhibition of *NO production can be shown to prevent demyelination, *NO may not act directly to damage myelin or myelinating cells, but rather act by the induction or enhancement of other factors. However there is substantial indirect evidence that *NO at least participates in demyelination, from work on a number of demyelinating diseases and disease models.

**Experimental Autoimmune Encephalomyelitis And Neuritis.** Experimental autoimmune encephalomyelitis (EAE) and neuritis (EAN) are primarily T cell-mediated inflammatory disorders of the CNS and PNS which serve as models of MS and Guillain-Barré syndrome (GBS) respectively. Increased proinflammatory cytokine expression has been demonstrated in both EAE (146) and EAN (220), implying that increased *NO production is likely to occur. Indeed, increased iNOS expression has been demonstrated in the CNS of animals with EAE. By measuring *NO levels directly using electron paramagnetic resonance (EPR), Lin et al. (136) found a statistically significant increases in the signal associated with iron-nitrosyl complexes in the spinal cords of mice with adoptive transfer EAE. Exogenously applied spin-traps have also been utilised with EPR to demonstrate increased *NO in the spinal cords of animals with both adoptive transfer (106) and actively induced (105) EAE. Unfortunately, absolute levels of *NO are difficult to determine, but these studies suggest that the level of *NO in the spinal cord in passive EAE lies between 6 and 30 μM (105, 106). This concentration is high (*NO functions as a physiological messenger at nanomolar concentrations), and higher than that at which *NO has effects on axonal conduction (183) (see below). Using reverse transcriptase polymerase chain reaction techniques (RT-PCR) (55, 130, 167) and ribonuclease protection assay (55), a significant increase (up to 10-30 fold) in iNOS mRNA has been demonstrated in the CNS of animals during the acute phase of adoptive transfer (55) or actively induced (130, 167) EAE. In contrast to animals with passive transfer EAE (55), animals with MBP-induced EAE demonstrate a second phase of iNOS up-regulation during the chronic phase of the disease (167), but this is not matched by a concomitant decline in neurological signs. Immunohistochemical techniques have revealed both increased iNOS expression in the spinal cords of mice with EAE (57, 167, 235), and immunoreactivity for nitrotyrosine, indicating the presence of peroxynitrite and its derivatives in the lesions (56, 57, 235).

**Multiple Sclerosis.** Indirect evidence that *NO plays a role in MS lesions includes the observations that pro-inflammatory cytokines including TNFα (104, 201) and IFNγ (36, 233) have been identified in astrocytes within MS lesions. IFNγ (137), IL-1 (149) and TNFα (162) have also been found within peripheral mononuclear cells and cells within the cerebrospinal fluid (CSF), and cultured peripheral monocytes have been shown to express more *NO in patients with active disease (197). Some studies have also shown that nitrite and nitrate (metabolites of *NO) are significantly elevated within the CSF of MS patients (56, 80, 119), and that the levels are directly related to disease state (56, 254). However, other studies found no such evidence in either MS or GBS (114).

There is, however, direct evidence that *NO is produced within MS lesions. iNOS mRNA is elevated in MS plaques (17), and is located chiefly in cells of the monocyte/microglial lineage (8, 62, 105). Dual-label histochemistry using anti-NOS antibodies and cell specific markers has shown that macrophages/microglia within actively demyelinating lesions express high levels of both iNOS (8, 62, 105) and cNOS (62). Astrocytes in active MS lesions have been reported to express cNOS (62) rather than iNOS (62, 105), and their expression of NOS is consistent with their positive staining for NADPH-diaphorase (17, 31, 62). Finally, as noted above, *NO can combine with superoxide to form peroxynitrite, and although this may be relatively short lived within lesions, it (or its derivatives) can nitrate tyrosine to produce the relatively stable "footprint" molecule nitrotyrosine. Increased nitrotyrosine reactivity is present in MS brains (8, 105), particularly in areas of demyelination and inflammation (56). Taken together these studies demonstrate the presence of increased production of *NO within MS lesions.

**Viral Demyelinating Disorders.** There is also direct evidence of *NO involvement in a viral disorder which has a demyelinating component. In mice infected with the coronavirus mouse hepatitis virus strain JHM (MHV-JHM), there is an acute, non-demyelinating phase, and a chronic, demyelinating phase. During the demyelinating phase, in situ hybridization and immunohistochemistry have demonstrated that iNOS expression is up-regulated in astrocytes in and around the demyelinated lesions (89, 224).

**Consequences Of Nitric Oxide Production On Cells Within The Nervous System.** Although the evidence presented above indicates that *NO production is increased in inflammatory demyelinating diseases, the
relative contributions made by \( ^\cdot \text{NO} \), compared with the derivatives of \( ^\cdot \text{NO} \), to pathophysiology remains unclear. Increasingly, it is felt that many of the actions formerly ascribed to \( ^\cdot \text{NO} \) may, in fact, be mediated by short-lived, but highly reactive, molecules, such as peroxynitrite and its derivatives. Significant amounts of peroxynitrite are likely to be generated, since every 10-fold increase in \( ^\cdot \text{NO} \) and superoxide formation leads to an approximately 100-fold increase in peroxynitrite formation (180). There is also evidence in vitro that where the concentration of the arginine substrate of NOS is low, the NOS enzyme can produce superoxide, resulting in peroxynitrite-mediated cytotoxicity (252). Certainly, \( ^\cdot \text{NO} \) toxicity is often enhanced considerably by the accompanying presence of superoxide (21, 169), and hence the presumed formation of peroxynitrite.

\( ^\cdot \text{NO} \) or peroxynitrite can have a wide variety of effects on cellular systems by modifying protein structure, and thereby function. The two main target sites for \( ^\cdot \text{NO} \) in the cell are thiols and metalloproteins. Nitrosylation of thiols to yield nitrosothiols (\( \text{R-SH} + ^\cdot \text{NO} = \text{R-SNO} + \text{H}^+ + \text{e}^- \)) occurs under physiological conditions (217) and appears to be controlled by the relative rates of production of \( ^\cdot \text{NO} \) and superoxide (246). Nitrosothiols can sometimes act like \( ^\cdot \text{NO} \) in biological systems, and they can function as temporary stores of \( ^\cdot \text{NO} \), effectively increasing its half-life. Although thiol interactions occur more readily, peroxynitrite (or a derivative from it) is also capable of nitrating tyrosine to form nitrotyrosine, and it has been reported that this reaction can be catalyzed by metalloenzymes such as SOD (115). Peroxynitrite can also nitrate tryptophan residues (3), although the physiological significance of this reaction is not known. Beckman et al. (11) have pointed out that even apparently simple reactions, such as the nitrosylation of thiols by \( ^\cdot \text{NO} \), may in fact be quite complex and involve the production of intermediates such as the nitrosionium ion.

\( ^\cdot \text{NO} \) has been shown to inhibit several enzymes, including protein kinase C (81), and enzymes involved in mitochondrial respiration including aconitase, NADH-ubiquinone oxidoreductase and succinate-ubiquinone oxidoreductase (216). Production of endogenous \( ^\cdot \text{NO} \) has been shown to inhibit mitochondrial respiration in cultured rat astrocytes (32). This is reflected in an inhibition of the mitochondrial respiratory chain enzyme nicotinamide dinucleotide-dehydrogenase in CNS macrophages/microglia isolated from animals with EAE (263). These actions on multiple members of the mitochondrial respiratory chain may be expected to cause deficits in cellular energy supplies, and indeed ATP content is reduced in neurons exposed to \( ^\cdot \text{NO} \). \( ^\cdot \text{NO} \) also affects the activities of several of the enzymes involved in oxidative defence, including catalase, glutathione peroxidase, and Mn-SOD which are all inhibited in C6 cells by exposure to an \( ^\cdot \text{NO} \) donor (68).

In addition to these effects, reactions of proteins with \( ^\cdot \text{NO}/\text{peroxynitrite} \) may have adverse consequences via the production of neo-epitopes which may provoke an immune reaction, including the production of antibodies. There is evidence to suggest that this phenomenon can occur in MS since some patients show a significant IgM antibody reaction to S-nitroso-cysteine (27).

Peroxynitrite can lead to cell death by several mechanisms, including the nitration of tyrosine residues thereby affecting signalling, direct interaction with DNA (for review see (225)), or by causing DNA strand breakages or deamination. Such breakages result in activation of the enzyme poly-(ADP)-ribosyl synthetase, which in turn leads to rapid depletion of cellular stores of NAD+ and ATP (34), and potentially to cell death. \( ^\cdot \text{NO} \) can also damage DNA directly by deamination (248), and inhibit the repair activity of the enzyme DNA ligase (85).

Both \( ^\cdot \text{NO} \) and peroxynitrite can affect lipid peroxidation (179), and this is an important consequence of \( ^\cdot \text{NO} \) production since lipid peroxidation can affect membrane fluidity and membrane permeability, and it can alter the function of proteins embedded in the lipid bilayer. \( ^\cdot \text{NO} \) and peroxynitrite can have opposing effects on lipid peroxidation, depending upon the circumstances. If superoxide production exceeds that of \( ^\cdot \text{NO} \), peroxynitrite is formed and this promotes lipid peroxidation (179, 190). If, however, the concentration of \( ^\cdot \text{NO} \) is high, lipid peroxidation is decreased because \( ^\cdot \text{NO} \) serves as a potent terminator of the radical chain propagation reactions involved. \( ^\cdot \text{NO} \) has this effect because it reacts directly with the alkoxyl and peroxyl radical intermediates formed during lipid peroxidation (179). \( ^\cdot \text{NO} \) was not found to induce lipid peroxidation, although this role has been claimed in some literature. The data show that \( ^\cdot \text{NO} \) formation can therefore have either prooxidant or antioxidant consequences depending upon the concentrations of superoxide and \( ^\cdot \text{NO} \). This diversity of action may help to explain the different effects observed in therapeutic trials based on \( ^\cdot \text{NO} \) inhibition in experimental models of inflammatory demyelination (see “Antioxidant Therapy” below).

Gangliosides often show neuroprotective properties, and it has been suggested that this effect may be due to the inhibition of \( ^\cdot \text{NO} \) formation (61). In support of this theory, the neuroprotective effects of gangliosides paral-
lel their potency in binding calmodulin in vitro (61), and thereby blocking *NO formation.

Sensitivity of Oligodendrocytes and Axons to *NO. Experiments with cultured oligodendrocytes by Merrill and colleagues (145) have yielded the potentially very important observation that these cells are more susceptible to *NO-mediated damage than are astrocytes or microglia. Furthermore, activated microglial cells appear to be able to produce sufficient *NO to lyse oligodendrocytes in co-culture, and this lysis can be prevented by antagonists of *NO production. It may be significant that oligodendrocytes are more sensitive to *NO-induced single stranded DNA breaks than are astrocytes or microglia (153), although oligodendrocyte death apparently occurs by necrotic, rather than apoptotic mechanisms (154).

Although MS is primarily a demyelinating disease, an important cause of the permanent disability in progressive disease is believed to be axonal loss. It may therefore be of interest that axonal loss appears to be related to the degree of inflammation in lesions (232), and that our recent studies have shown that *NO may play a role in axonal loss (213). This role may be accentuated if *NO exposure occurs in conjunction with physiological levels of axonal impulse activity (213).

Effects of nitric oxide on ion channels and the electrophysiological function of axons. In recent years it has become clear that the inflammatory response can play an important part in the pathophysiology of inflammatory demyelinating diseases (156, 258). The data suggest that inflammation can cause axonal conduction block, and that this can lead to significant symptomatology in these conditions. How inflammation causes conduction block in human disease is not known, but recent studies in our laboratory (183) have demonstrated that *NO, or its derivatives, can block conduction in central and peripheral axons in vivo, and similar observations have been made by Shrager’s group in vitro (204). Interestingly, we found that demyelinated axons were especially vulnerable to *NO-mediated block, and that this effect was observed at concentrations of *NO anticipated at sites of inflammation (183). These observations raise the intriguing possibility that *NO production may be responsible for some of the symptoms in MS and other inflammatory demyelinating disorders. If so, then strategies to lower *NO concentrations may form an effective therapy for patients with MS. The mechanism(s) underlying *NO-mediated conduction block are not yet known, but may involve direct effects of *NO on ion channels. The redox state of thiols is well known to affect the conduction properties of axons (reviewed in (188)), and several studies have shown that *NO can act as a modulator of ion channel currents. Consistent with such findings, *NO has been found to inhibit both action potential discharge (143) and sodium currents in baroreceptor neurons (135). *NO also affects currents through Ca++-dependent potassium channels (22), photoreceptor Ca++ channels and glutamate ionotropic channels (71).

Actions of *NO involving cGMP are well known (74), but these effects appear to be independent of cGMP, and are apparently due to direct interaction with the channel (see also (39)). Surprisingly, the block of axonal conduction observed in vitro was dependent upon an intact nerve sheath (204). This observation argues against a direct effect of *NO on ion channels, and the authors proposed a mechanism where an endoneurial intermediate molecule may react with *NO and then with the ion channel.

Taken together, the findings from this and the preceding section suggest that *NO may play an important role in MS, possibly affecting demyelination, conduction block and axonal loss.

The Role Of Reactive Oxygen Species In Demyelination

Production Of Reactive Oxygen Species. In common with other tissues, neural tissues generate ROS constantly as part of their normal functioning. Potential sources of ROS include enzymatic pathways in the mitochondrial electron transport chain, xanthine oxidase, NADPH oxidase, lipoxygenase and cyclooxygenase, as well as non-enzymatic mechanisms such as the auto-oxidation of dopamine and noradrenaline. Mitochondrial respiration is an important source of ROS within the brain, since this organ utilises approximately 20% of the total oxygen taken in each day, and approximately 3% of this is converted to superoxide. Peroxisomes are another source of ROS, and they are abundant in oligodendroglial cells during the period of active myelination.

Although resting microglia produce only small quantities of ROS, this can increase substantially upon their activation (e.g. with IFNγ (251) or phorbol myristate acetate (196), and it may be significant that microglia can become highly activated in inflammatory demyelinating lesions. Cultured human microglia activated by phorbol myristate acetate are especially potent in superoxide production in comparison with other species (43) see also (227), and production is significantly further increased if the microglia are “primed” by exposure to the pro-inflammatory cytokines IFNγ or IL-1α (46):
such exposure would be expected in an inflammatory lesion. The superoxide is produced largely extracellularly as part of the “respiratory burst” phenomenon common to macrophages, neutrophils etc, and mediated by the membrane-bound NADPH oxidase (98, 196), although other generators may also be involved (44). Cells capable of significant superoxide production via the respiratory burst can be recruited to lesions within the nervous system in inflammatory demyelinating diseases. Phagocytic cells are known to be closely associated with myelin sheaths in some such disorders and may act as a concentrated source of ROS. The ROS and RNS formed may directly damage the myelin sheath, promoting attack by macrophages. Indeed, peroxynitrite converts low density lipoprotein to a form recognised by the macrophage scavenger receptor (84).

Neurons may make an important contribution to ROS production, since it is known that neuronal electrical activity can promote the formation of ROS (23). Important mechanisms probably include the direct transaxolemmal entry of calcium ions as part of excitatory activity, and the release of calcium from intracellular pools. The calcium ions can activate phospholipase A2, leading to the release of arachidonic acid and the initiation of the cascade resulting in the formation of prostaglandins, leukotrienes and thromboxanes by cyclooxygenases and lipoxygenases. These enzymes utilise molecular oxygen, and can generate ROS as they function. It may be significant in this respect that axonal activity may be greater than normal in demyelinating diseases such as MS. The increase can result either from the development of sustained, spontaneous, repetitive discharges in demyelinated axons (122, 214, 212), or from the enhanced firing rates of spared axons presumed to occur in compensation for the function lost in axons blocked by demyelination (211). Massed synchronous discharges have also been reported. Electrical activity, especially the massed activity which has occasionally been reported in demyelinating disease (212), is also accompanied by a significant increase in extracellular potassium concentration. Elevated potassium levels may be predicted to be especially large in those MS lesions which have a reduced density of astrocytes (e.g. “open” lesions (9)), since these cells are believed to buffer the extracellular potassium concentration. The raised extracellular potassium concentration may raise ROS levels further since it has been found to increase superoxide production by cultured microglia activated by exposure to phorbol myristate acetate (45).

Inflammatory demyelinating lesions, such as those in MS and GBS, are also likely to contain T lymphocytes among the inflammatory infiltrate. These cells have not been shown to produce ROS as part of their normal function, but a modification of their mitochondria can result in superoxide production during the early stages of apoptosis (142, 260). Since these cells are not known to produce "NO it is interesting that CD4+ cells can show immunoreactivity for nitrotyrosine in EAE lesions (57). Nitrotyrosine is a marker for the former presence of peroxynitrite, and it is possible that this potent oxidising agent is formed by the combination of "NO diffusing from nearby cells reacting with superoxide produced by imminently apoptotic T cells (57).

Mature oligodendrocytes are not believed to be major producers of ROS, but increased ROS formation is likely to occur in oligodendrocytes during myelination. This increase arises both because of the energy demands of myelin formation, and because myelin synthesis involves lipid synthesis in peroxisomes. These organelles increase in number during myelogenesis (5), and they can produce significant quantities of superoxide, and thereby the production of hydrogen peroxide through the action of SOD ((234) see also below).

**Evidence For Increased ROS Production In Inflammatory Demyelinating Disease.** There is convincing evidence that ROS production is a prominent feature of inflammatory demyelinating diseases. The evidence is derived from observations in animal and human disease, and by inference from the success of several therapeutic trials based on the manipulation of ROS production (see “Antioxidant Therapy”).

**Lipid Peroxidation.** Evidence of ROS generation in the brains of patients has been derived either indirectly, from measurements of the products of lipid oxygenation during the course of the illness, or directly, after death. The indirect evidence has been partly conflicting. An early study found evidence of lipid peroxidation in the CSF of patients with MS, but not in the plasma (111), but a subsequent study found evidence in the serum, but not the CSF (158) see also (81). In the latter study (158), no correlation was identified between levels of lipid peroxides and disease severity or time since relapse. However, as the authors pointed out, few of their patients had severe disability or a long relapse-free interval. The authors considered that elevated CSF levels of peroxidation products were absent either because there was no increase in CSF lipid peroxidation or, more likely, because CSF lipid peroxides were removed rapidly following their generation. Another study (35) found evidence of significantly higher concentrations of malondialdehyde in patient CSF, together with altered levels
of enzymes involved in oxidative defence: the activity of glutathione reductase was significantly increased, whereas the activity of glutathione peroxidase was markedly decreased. In a recent study, lipid peroxidation in plasma and CSF samples were not detected above control levels in patients with MS or aseptic meningitis, but a significant increase was detected in plasma samples from patients with GBS (91). The authors drew a tentative correlation between this finding and the observation that plasma exchange can shorten the course of disease in GBS. Raised concentrations of the antioxidant protein haptoglobin were detected specifically in GBS, but no significant increase was detected in lipid peroxidation in the CSF of GBS patients (91). Evidence of lipid peroxidation was sought in another study by measuring the breath levels of pentane (derived from linoleic acid) and ethane (derived from linolenic acid) as markers (231). Ethane levels were found to remain stable, but pentane rose significantly during acute exacerbations of MS. Excretion of pentane subsequently fell when patients entered clinical remission. However, it has subsequently been claimed that all measurements of breath pentane may be invalid due to technical artifacts (215).

Direct evidence of lipid peroxidation has been demonstrated in post-mortem MS brain. High pressure liquid chromatography was used to demonstrate an increase in uric acid in MS plaques, with a corresponding decrease in glutathione (132). The levels of the lipid radical scavenger vitamin E (α-tocopherol) were lowest in plaques and highest in distant white matter. Newcombe et al. (164) used immunocytochemical techniques to detect low density lipoprotein (LDL) and LDL modified by the lipid peroxidation products, malondialdehyde and 4-hydroxynonenal in early and actively demyelinating plaques. Both LDL, which may enter the CNS after blood brain barrier damage in the acute inflammatory lesion, and its oxidation product were found in foamy macrophages within lesions, and also in astrocytes. These findings point to lipid peroxidation as an early event in the evolution of the plaque. Further direct evidence of oxidative damage to lipids, and proteins, in MS lesions has recently been detected using Fourier transform infrared microspectroscopy (134). Data were obtained with near microscopic resolution, and revealed that while normal areas of MS white matter had similar spectra to control white matter, spectra from within MS lesions indicated an increase in the C=O to CH₂ ratio, suggesting lipid oxidation. Other data were consistent with the oxidation of proteins (134). The brain tissue had been fixed in formalin, but control studies suggested that fixation itself did not affect the data obtained.

The failure of an earlier, similar study (40) to detect changes consistent with oxidative damage was attributed to earlier technical limitations, and study of chronic inactive plaques rather than the active plaques studied by LeVine and Wetzel.

Lipid peroxidation can result in the release of a number of membrane components, including arachidonic acid. Arachidonic acid can be converted to prostaglandins by the enzyme cyclooxygenase and also to isoprostanes by the non-enzymatic free radical-catalysed peroxidation of arachidonic acid (241). The isoprostanes, particularly 8-epi-PGF₂α, are used as indicators of oxidative stress (64, 185). The production of these pro-inflammatory compounds may evoke further tissue damage. For example, it appears that prostaglandin E₂ can act in conjunction with NO to disrupt the blood brain barrier (117). A role for oxidant species in barrier breakdown is supported by the observation that administration of a 21-aminosteroid antioxidant (one of a group of compounds known as “lazaroids”) can attenuate barrier disruption induced by arachidonic acid (96). The prostaglandins are not necessarily damaging to tissues, however. Administration of a long-acting analogue of prostaglandin E₂ has been found to suppress EAE (182). The details concerning the effects of ROS on the blood-brain barrier are the subject of recent reviews (63, 147).

Other evidence for ROS production. Other evidence for ROS production in MS has centred on the examination of blood cells obtained from patients. Studies in 1986 found that the antioxidant enzymes SOD (4) and glutathione peroxidase (118) were lower in erythrocytes and haematogenous cells, respectively, of patients than neurological controls. In keeping with an altered redox state, it has been found that red cell glutathione peroxidase levels are depressed in MS, with similar reductions occurring in circulating lymphocytes and granulocytes (205). Furthermore, stimulated monocytes from patients with MS were found to produce significantly more hydrogen peroxide and superoxide than monocytes from controls (73). The authors concluded that blood monocytes in MS patients are “primed” so that they produce more ROS than normal when exposed to inflammatory stimuli. A subsequent study (81) obtained similar results using whole blood. A finding that red blood cells in patients with MS displayed increased mechanical fragility has been attributed to free radical-mediated damage to lipids in the red cell membranes (37, 198).

Several studies have examined ROS production in experimental models of inflammatory demyelinating disease. A role for hydrogen peroxide was suggested by findings in actively-induced EAE (93). The evidence...
suggested raised hydrogen peroxide concentrations in the myelinated portion of the optic nerve in the early preclinical phase of the disorder when the blood brain barrier was expected to be initially disturbed. The authors proposed that the hydrogen peroxide acted both alone, and through the generation of free radicals in a cascade of lipid peroxidation and demyelination. Examining rats with clinical signs of EAE, Ruuls and colleagues found that macrophages and microglial cells exhibited significantly higher spontaneous levels of ROS compared with controls (192). Similarly, and examining the same model, a later study found significantly higher levels of superoxide in all the CNS regions examined (200). Where superoxide is formed in the presence of *NO, the agents combine to form the strong oxidising and nitrating agent peroxynitrite, and a recent study found evidence that peroxynitrite is formed very early during the course of EAE, correlating with disease activity (235). The labelling was present in macrophages/microglia, which also showed iNOS reactivity.

**Consequences Of ROS Production.** An important consequence of ROS formation is the promotion of inflammation via effects on endothelial cells, chemotactic signals and the release of products from the arachidonic acid cascade. These effects are beyond the range of this review, but inflammation can affect the progression of demyelinating lesions, and perhaps its immunological consequences.

**Effects Of ROS on Oligodendrocytes.** The death of oligodendrocytes, the central myelinating cell, is an early event in many demyelinating lesions in MS (33, 176), but the circumstances which cause the death of the oligodendrocyte remain uncertain. This uncertainty applies even though MS is believed to be an autoimmune disease directed against myelin or the myelinating cell. There is now evidence that ROS may play a role in oligodendrocyte death, in addition to the potential role for *NO described above.

Several studies have examined the sensitivity of cultured oligodendrocytes, and their precursors, to damage by ROS. These studies followed observations by Griot and colleagues that the demyelination caused in dogs by infection with the canine distemper virus may be due to ROS released by brain macrophages (86, 87). The culture of dog oligodendrocytes in the presence of ROS generated by the xanthine/xanthine oxidase reaction (an experimental system to generate superoxide), revealed that the oligodendrocytes were killed at ROS concentrations which did not appear to affect astrocytes or brain macrophages (88). Similar findings were subsequently made with bovine oligodendrocytes, which could be completely protected from death by the inclusion in the medium of catalase, an enzyme which degrades hydrogen peroxide to water, but not by the inclusion of the antioxidants SOD, DMSO, vitamin E or glutathione (124). The implication that hydrogen peroxide was responsible for the damage was consistent with findings from other cultured cell types and was also implicated in the toxicity of oligodendrocytes, from adult rat brain, arising from exposure to the catecholamines norepinephrine and epinephrine (165). Catecholamine metabolism can generate ROS, including hydrogen peroxide, and it is significant that the catecholamine toxicity could be prevented by catalase, and reproduced by the addition of equimolar concentrations of exogenous hydrogen peroxide. However, the toxicity is not necessarily due to hydrogen peroxide directly, even though it is a mild oxidant, since the toxicity may rather be due to the formation of the highly toxic hydroxyl radical through the action on hydrogen peroxide of transition metals such as iron and copper (98): oligodendrocytes are particularly rich in iron (see below).

Hydrogen peroxide is also produced in quantity in peroxisomes (234). Peroxisomes are particularly abundant in oligodendrocytes during the period of active myelination (5), raising the possibility that oligodendrocytes may be particularly vulnerable to oxidative stress during this period. If so, then oligodendrocytes may also be vulnerable during the repair, by remyelination, of demyelinating lesions in MS and other demyelinating disorders (176, 177). In contrast to normal development, repair by remyelination in MS occurs in the context of an on-going inflammatory disease involving increased levels of ROS production. Indeed, repair by remyelination can be observed in conjunction with on-going inflammation (181). It is therefore possible that in response to the combined demands arising from remyelination and exogenous ROS production, some oligodendrocytes may undergo degeneration, contributing to the long term failure of repair by remyelination in this disease.

Apart from having a direct effect on oligodendrocytes, ROS can also directly affect both the lipid and protein components of myelin (66, 129). Thus the incubation of myelin with ROS generated in vitro resulted in lipid peroxidation and the decompaction of myelin lamellae along the intraperiod line (24). The incubation also caused the marked peroxidation of myelin basic protein and proteolipid protein, and this rendered the proteins susceptible to trypsin degradation (25). It is
therefore possible that in inflammatory demyelinating disease, exposure to ROS may render myelin susceptible to degradation by extracellular proteases, such as those liberated by macrophages. The decompaction of the lamellae may also facilitate access of proteases to the myelin proteins (25).

An unexpected consequence of ROS/RNS production is the release of active matrix metalloproteinases (MMPs) from their proenzyme form, via the formation of either peroxynitrite or the nitrogen dioxide radical (140). Moreover, hydrogen peroxide exposure has been found to cause an increase in the mRNA and protein expression for MMP-1 (interstitial collagenase) in cultured human fibroblasts (29). The formation and release of MMPs may be relevant to demyelination since some MMPs have been shown to be able to degrade myelin basic protein (38, 77). Furthermore, inhibitors of MMP release have been shown to protect animals from both EAE (52, 76, 103) and EAN (184), the animal models of MS and GBS respectively. However, the net effect of RNS formation on MMP activity is difficult to predict since peroxynitrite has also been found to inhibit some MMPs (169).

Demyelination can also follow ischaemic episodes, or periods of hypoperfusion of the brain. Lesions resulting from hypoxic-ischaemic insult typically involve the grey matter, but delayed white matter lesions are quite common, and primary demyelination (i.e. myelin loss with sparing of axons) can result when the insult affects white matter (78, 79). The consequences of ischaemia are the subject of another review in this symposium, but it is appropriate to mention here the occurrence of primary demyelinating lesions induced in Mongolian gerbils by hyperoxia following transient brain ischaemia (150). This protocol is anticipated to encourage ROS formation, and it resulted in lesions in the corpus striatum, lateral thalamus, mesencephalon and internal capsule. Lesion formation correlated with the administration of 100% oxygen following the transient ischaemia. Delayed primary demyelinating lesions have also been produced in rats and gerbils with chronic hypoperfusion, indicating that mild hypoxia, combined with mild hypoglycemia, can preferentially affect oligodendrocytes (101, 239), reviewed in (120). Interestingly, carbon monoxide exposure results in vivo in an increased production of hydroxyl radicals (174), and lipid peroxidation (229), and some patients have been reported to show a delayed primary demyelination following carbon monoxide poisoning (78, 79).

A consequence of ischaemia in grey matter is the release of the neurotransmitter glutamate. Adult rat oligodendrocytes are much more vulnerable to glutamate-induced cell death than astrocytes (succumbing to 200μM glutamate, whereas astrocytes are resistant to 5mM (166)). However, the extent to which oligodendrocytes are exposed to glutamate in demyelinating disease is uncertain. Examination of CSF from patients with MS has resulted in reports that glutamate concentrations can decrease (1, 2, 178), remain unchanged (127), or increase (221). The increased (221) concentration occurred in acute MS patients, and consisted of a doubling of glutamate concentration. Serum/plasma glutamate has more consistently been reported to increase in MS (178), especially during relapses (243). In inflammatory MS lesions, glutamate concentrations might rise since astrocytic glutamate uptake is inhibited by the pro-inflammatory cytokines TNFα, IFNγ and IL-1β, at least in vitro (255). Glutamate is toxic to cultured oligodendrocytes through free radical attack consequent to the depletion of cystine, and thereby depletion of the antioxidant glutathione (166). Glutathione depletion consequent to cystine deprivation also kills cultured oligodendrocytes (256). In each case, the cultured oligodendrocytes could be protected by the addition of free radical scavengers, including vitamins C and E.

**Particular Sensitivity of Oligodendrocytes to ROS.** A characteristic of established lesions in MS is the presence of demyelinated axons embedded among astroglial processes, with few, if any, oligodendrocytes. A factor contributing to this appearance may be the much greater resistance to ROS of astrocytes, in comparison with oligodendrocytes. It appears that several factors contribute to the comparative sensitivity of oligodendrocytes to ROS. For example, recent studies have revealed that cultured oligodendrocytes at several stages of differentiation (proliferative oligodendrocyte progenitor, proliferative oligodendroblast and mature oligodendrocyte) have less than half the glutathione content of astrocytes (121, 230). A low level of this important antioxidant is also apparent in vivo (210), and appears to be due in part to a low rate of glutathione synthesis, and in part to their having only half the glutathione reductase activity of astrocytes, and a particularly low level (15% of astrocytic) of glutathione peroxidase activity (121). In addition, cultured oligodendrocytes fail to express MnSOD, even when exposed to ROS, in contrast to microglia and some cultured astrocytes (175). Furthermore, immunocytochemical studies have revealed the absence of metallothionein in oligodendrocytes (159, 6), although appreciable quantities are present in astrocytes (15, 16, 160). Metallothionein is a protein particularly rich in cysteine (25-30%), making it an effec-
reactive astrocytes and binding agent for zinc and copper (70). Metallothionein is induced by cytokines, particularly IL-1 (123), and it is expressed at high concentration in reactive astrocytes in vivo (60, 163). The absence of Mn-SOD and metallothionein in oligodendrocytes removes two more avenues of antioxidant defence from this cell.

A Role For Iron. The increased oxidative risk experienced by oligodendrocytes by virtue of their relative paucity of antioxidant defence is exacerbated by the fact that these cells contain most of the iron in the brain (48-50, 75). It is well known that reduced iron, probably in low molecular weight complexes such as iron-ADP and iron-citrate, can promote oxidative damage in vitro by catalysing the formation of hydroxyl radicals from hydrogen peroxide and causing secondary initiation of lipid peroxidation. Most of the iron in cells is in a "safe" form attached to the binding proteins transferrin and ferritin (48-50, 75), and in this form it is not available to catalyse free radical reactions. However, if this iron were to be released it could catalyse peroxidative chain reactions that could spread the effects of the injury over a wider area. It is notable in this regard that superoxide (and other reducing compounds such as vitamin C) can release iron ions from ferritin, and that hydrogen peroxide can release iron from haemoglobin (at high hydrogen peroxide:haemoglobin ratios (92)). Thus superoxide and hydrogen peroxide can create the conditions that lead to hydroxyl radical production, although the extent to which this occurs in vivo is not clear. In vitro, it has been demonstrated that activated microglia can release iron from ferritin, and that the release of iron is mediated through superoxide production by the microglia since it is blocked by SOD (257). Interestingly, the oxidative stress experienced by cultured oligodendrocyte precursors when exposed to blue light (which excites compounds such as riboflavin ultimately resulting in increased hydrogen peroxide production) could be prevented either by chelating intracellular free iron, or by raising the concentration of intracellular glutathione to astrocytic levels (230).

Oligodendrocyte precursor cells appear to be particularly sensitive to ROS in comparison with astrocytes, and in mixed glial cultures they are preferentially damaged by measures designed to increase intracellular ROS production (112). Preoligodendrocytes also appear to be significantly more sensitive than mature oligodendrocytes to oxidative stress (7).

Although there is agreement that oligodendrocytes are more vulnerable to oxidative stress than astrocytes (245), a recent study found that cultured mouse astrocytes were "exquisitely sensitive" to oxidative stress, and that their vulnerability was related to, and enhanced by, iron (187). Much of the work cited above was performed in vitro, with purified cell cultures. Caution is always required before extrapolating in vitro data to the condition in vivo, but it is particularly so here since there is evidence that oligodendrocytes may not be as sensitive to ROS in vivo as the in vitro data suggest. Thus it has been found that the inclusion of a monolayer of neonatal rat astrocytes completely prevented the catecholamine toxicity described above (165): astrocyte conditioned medium provided no protection. Also, neurons co-cultured with astrocytes have markedly elevated concentrations of the antioxidant glutathione when compared with neurons cultured alone (20, 194). Oligodendrocytes in vivo may therefore be more resistant to oxidative stress than the available data suggest.

Using histochemical techniques which can detect non-haem iron, deposits of iron have been found in post-mortem MS plaques in some cases. For example, using methods to increase the sensitivity and accessibility of tissue iron to histochemical reagents, iron deposits have been found to occur frequently in post-mortem MS brain. The iron is seen in controls and pathological tissues in both oligodendrocytes and in myelin, but in plaques it is also present in reactive and amoeboid microglia and in macrophages (133). In one out of five cases, iron was also detected in some axons near damaged areas of the white matter. It appears, therefore, that iron is present at sites where it could promote oxidative damage in the brains of patients with MS.

An early report suggested that actively-induced EAE could be suppressed by treatment with the iron-chelating agent desferrioxamine B mesylate (28) see also (94). A later study found that passively-induced disease could not be suppressed in this way (244). A potential explanation for these different findings was that the chelating agent was actually working by suppressing antigen presentation in the afferent limb of the autoimmune response (244). However, a recent finding has found a reduction in clinical signs when animals were treated with desferrioxamine during the active stage of MBP-induced disease (172).

Interaction Between Oxidative and Nitrative Stress. Although the combination of NO and superoxide to form peroxynitrite is well established, it has also been reported that NO can actually reduce superoxide production arising from the respiratory burst (41, 126). This reduction is not due to scavenging of the superoxide, but rather to some other mechanism, which appears not to be mediated by guanylyl cyclase or cGMP. It has been noted that the reduction of superoxide generation may serve to limit the deleterious effects of excessive peroxynitrite forma-
tion (126). This potentially beneficial effect of *NO is counterbalanced by the fact that *NO can decrease the activity of some of the enzymes involved in anti-oxidant defense in cultured oligodendrocyte-like cells. Thus, although exogenously or endogenously produced *NO increased the activity and protein level of Cu/Zn-SOD, it was found to decrease the activities of the antioxidant enzymes glutathione peroxidase, catalase and Mn-SOD, probably through the down regulation of the expression of their mRNAs (68). *NO may also inactivate glutathione peroxidase directly by modifying essential cysteine-like residues in the enzyme. Such observations indicate that *NO production may affect the level of oxidative stress and the effects of ROS production. If *NO reduces the antioxidant defense of oligodendrocytes in early inflammatory MS lesions, namely a location where the cells will be exposed to a range of ROS and RNS, it would provide additional explanation for the loss of these cells and the formation of a demyelinating lesion.

**Beneficial Effects of ROS and RNS.** This review has focused on the deleterious role of ROS and RNS in promoting demyelinating pathology, but it should be appreciated that these species also serve many beneficial, physiological functions (e.g. *NO functions as a messenger by binding to guanylate cyclase) which are beyond the scope of this review (see (10, 74, 98, 249)). *NO, in particular, may also serve beneficial functions under pathological circumstances. It can, for example, react with organic radicals and it can stop chain radical reactions. Perhaps as a consequence of such reactions, several experiments have found that blocking *NO production in EAE is sometimes detrimental (see “Antioxidant Therapy” below). Indeed, *NO is known to exhibit some anti-inflammatory properties, such as decreasing the proliferation of lymphocytes in vitro (65), inhibiting the adherence of leukocytes to the vascularature and infiltration into the tissue (131), and decreasing IFNγ production by Th1 T lymphocytes (228). Other protective effects of *NO include protection from superoxide- or hydrogen peroxide-mediated damage to cells in vitro, perhaps achieved by blocking the formation of hydroxyl radicals (247).

**Antioxidant Therapy.** As reviewed above, there is substantial evidence that RNS and ROS are involved in demyelination, and in demyelinating disease. This evidence has spawned a number of examinations of antioxidant and antiinflammatory therapies, both in vitro and in vivo, as described below.

We have already mentioned the observation that oligodendrocytes in vitro are very sensitive to the effects of ROS, and that they can be protected from ROS- and catecholamine-induced cell death by the addition of catalase to degrade hydrogen peroxide (124, 165). Oligodendrocytes can also be rescued from glutamate-mediated death by supplementation with cystine or cysteine (166). Also, another antioxidant (N-acetyl-L-cysteine (NAC), which can effectively raise intracellular glutathione levels) is able to protect cultured oligodendrocytes from toxicity mediated by the pro-inflammatory cytokine TNFα (144): there is evidence that TNF toxicity in culture is mediated via ROS (199, 250). Such observations encourage a belief that antioxidant therapies may be of value in demyelinating diseases such as MS, and this possibility has been examined in vivo using animal models.

Hartung et al. (100) found that early treatment of rats with the antioxidants catalase or SOD protected against actively-induced EAE, and that even if treatment was delayed until after the onset of neurological deficit (i.e. a clinically relevant regimen) the agents were still effective in markedly reducing the severity of disease. This important demonstration that ROS may be involved in peripheral autoimmune demyelinating disease was followed in 1992 by the observation that one of the 21-aminoesteroid antioxidants was effective in reducing the incidence and severity of actively-induced EAE in the CNS (95). The administration of catalase before the onset of neurological deficit was also found to delay the onset of EAE and to reduce its severity and duration (192). Furthermore, another antioxidant, butylated hydroxynisole, was effective in reducing the incidence, severity and mortality of passively-induced EAE (99). A synthetic catalytic scavenger of oxygen radicals, EUK-8, also ameliorated EAE in mice (141). This evidence for the involvement of ROS was accompanied in 1994 by the demonstration that RNS may also be involved. Several investigators have shown that aminoguanidine, a weak but preferential inhibitor of the inducible/inflammatory form of NOS, inhibits the expression of disease in mice and rats with actively-induced EAE (30, 58, 261) and inhibits demyelination induced by Theiler’s murine encephalomyelitis virus (189). Also, the use of antisense knockdown of iNOS in mice has been shown to inhibit EAE (67). Additional data supporting a view that decreasing *NO concentrations may be of therapeutic value have been presented by Hooper et al. (105, 107). These authors found that the inhibition of iNOS induction (using tricyclodecan-9-yl-xanthenogenate), or scavenging of *NO (using 2-phenyl-4,4,5,5-tetramethyleneimidazoline-1-oxyl-3-oxide) or peroxynitrite (using uric acid), inhibited neurological disease in mice.
with actively-induced EAE. Withdrawal of the iNOS inhibitor resulted in the expression of neurological signs within 24 hours.

The evidence described above provides a seemingly unambiguous argument for the value of antioxidant therapy in inflammatory demyelinating disease. However, data reported in 1995/6 (193, 262) suggested that the inhibition of nitric oxide production is not always beneficial, and the most recent data (54) indicates that such inhibition can be lethal. ZIELASEK and colleagues (262) used several inhibitors of nitric oxide synthase, namely NG-L-monomethyl arginine (L-NMMA), which is relatively non-specific for different NOS isozymes, aminoguanidine, which is relatively selective for the inducible form of NOS, and two other inhibitors. They examined the effects of these inhibitors in different models of experimental autoimmune disease. L-NMMA partially suppressed passively-induced EAN (i.e. EAN induced by the injection of neuritogenic T-cells), but not actively-induced EAN or passively-induced EAE. Aminoguanidine enhanced actively-induced EAE, and had no significant effects on actively-induced EAN. The other NOS inhibitors had little or no effects in EAN and EAE. As the authors noted, the diversity of action indicates that the *NO pathway may play a more complex role in disease than previously suggested. Ruuls et al. (193) found that the NOS inhibitors N(omega)-nitro-L-arginine and N(g)-monomethyl-L-arginine, exacerbated actively-induced EAE. Another study (54) also found that NOS inhibition, by aminoguanidine, exacerbated actively-induced EAE. Other recent data has revealed that iNOS knockout mice have more severe EAE (72, 195). Indeed, the complexity was highlighted further by the observation that another NOS inhibitor, N-methy-L-arginine (NMA), could induce disease in PVG rats, which are normally resistant to actively-induced EAE (193). The disease in PVG rats was fulminating in nature, and accompanied by some mortality. Interestingly, in the absence of NOS inhibition, PVG rats were found to develop higher serum nitrite and nitrate levels (surrogate markers of *NO production) than did Lewis rats, even though Lewis rats are susceptible to EAE. This data suggested that *NO may actually protect PVG rats from disease, and additional *in vitro* data indicate that this protection may be due to the inhibition by *NO of T cell proliferation (54).

A role for antioxidants in MS has been suggested by many authors e.g. (51, 113, 242), but no large scale trials have been conducted. However, therapy with IFNβ has been shown to reduce the relapse rate and possibly clinical progression (97, 191). It is often proposed that IFNβ produces its beneficial effects by mechanisms involving immune modulation. However, it has recently been realised that IFNβ also impairs the ability of astrocytes *in vitro* to form iNOS in response to inflammatory stimuli, such as exposure to the cytokines IL-1β and IFNγ (90, 109, 218, 219). IFNβ also downregulates the level of steady state expression of iNOS in cultured astrocytes (109). These observations raise the possibility that, in part at least, IFNβ may effectively be functioning in MS as a component of the antioxidant defence. If so, then other therapies based on this strategy may also be beneficial. The role of nitric oxide in MS has been examined in a recent review (171).

The variable observations obtained with the use of NOS inhibitors in experimental autoimmune demyelinating disease may be related to the relative lack of potency and specificity of the inhibitors, or to inopportune timing of the therapy in the course of the disease: *NO has immune regulatory effects as well as cytotoxic ones (see above), and so the timing of administration could be critical. Theory suggests that if *NO inhibition can be an effective therapy for MS, an ideal *NO inhibitor would be one which was specific for iNOS, since this would leave the eNOS and nNOS enzymes unaffected, permitting normal physiological function to continue. [However, it may be worth mentioning evidence that iNOS can be induced in response to non-inflammatory, non-immunologic, or inapparent stimuli, and so even a specific inhibitor may have unwanted “side” effects (see discussion in (161)).] When such an inhibitor is discovered it will be interesting to consider whether it may best be employed in conjunction with neurotrophic therapy. Evidence has recently been advanced suggesting that at least one of the neurotrophins, brain-derived neurotrophic factor (BDNF), limits its own neuroprotective potential by inducing NOS, and thereby damaging *NO production (128) see also (144). The data showed that whereas neither BDNF nor a free radical inhibitor (either the spin trap S-PBN or the NOS inhibitor L-NAME) effected significant survival of retinal ganglion cells from axotomy-induced death, the agents acted synergistically upon co-administration to rescue significant numbers of RGCs.

Hyperbaric oxygen has been advanced as a therapy in MS following positive findings in EAE (240). Clinical trials have failed to demonstrate any beneficial effect (125), but the findings in EAE remain unexplained. It has been reported (4) that exposure of MS patients to hyperbaric oxygen resulted in a significant increase in erythrocyte SOD levels, indicating an increase in cellular oxidative defence. It seems likely that the exposure
to hyperbaric oxygen resulted in an increase in superoxide, and that this induced the formation of oxidative stress enzymes. If such enzymes were also induced in CNS cells, it would increase the tolerance of the cells to oxidative stress and this could help to explain the beneficial effects in animals (242).

**Future Therapy of MS and GBS from an antioxidant perspective.** It seems likely that peroxynitrite, or one of its derivatives, plays a role in the development of MS lesions, given the presence of nitrotyrosine labelling within lesions (56, 57, 235). This view is supported by the efficacy of a trial therapy based on peroxynitrite scavenging using uric acid (105, 107) (although uric acid actually scavenges several reactive species, not just peroxynitrite). Since peroxynitrite is formed by the combination of superoxide and NO, peroxynitrite formation can be diminished by inhibiting the production of either of these molecules: it is not necessary to inhibit both. Indeed, strategies aimed at reducing the formation of either molecule have produced beneficial effects in EAE (30, 58, 67, 95, 99, 100, 105, 107, 141, 192, 261). It is too early to state with any certainty whether superoxide or NO (if either) will form the best target for new therapies in human demyelinating disease. Current electrophysiological evidence from our laboratory shows that exposure to NO donors can promote conduction block (183) and axonal degeneration (213), and such observations appear to recommend therapeutic strategies based on decreasing the concentration of NO. However, the effector molecule (whether NO, peroxynitrite or another NO derivative) in the electrophysiological experiments is not yet clear. Furthermore, therapies designed to decrease NO concentrations (54, 72, 193, 195, 262) have been less consistently beneficial in experimental demyelinating disease than those designed to limit superoxide. This latter consideration favours the development of strategies to inhibit extracellular superoxide formation within lesions. Such strategies may also limit the formation of hydrogen peroxide, a molecule which appears to be quite toxic to oligodendrocytes (124, 165). The pace of research into the roles of ROS and RNS in demyelination is accelerating rapidly, and the optimal strategy may soon become clearer.

**Acknowledgements**

We gratefully acknowledge the support of the Medical Research Council, the Multiple Sclerosis Society of G.B. & N. I., and the Special Trustees of Guy’s & St. Thomas’s Hospitals in the preparation of this manuscript. We thank Prof. C Rice-Evans, Dr. NA Gregson and Prof. RAC Hughes for their expert comments on a draft of this manuscript.

**References**

1. Ali QG, Baig SM, Parvez SH (1997) Neurotoxicity and possible roles of aspartic acid, glutamic acid and GABA in some neurologic disorders. Biogenic Amines 13: 565-578
2. Ali QG, Halawa A, Baig S, Siden A (1996) Multiple sclerosis and neurotransmission. Biogenic Amines 12: 353-376
3. Alvarez B, Rubbo H, Kirk M, Barnes S, Freeman BA, Radi R (1996) Peroxynitrite-dependent tryptophan nitration. Chem Res Toxicol 9: 390-396
4. Ansari KA, Wilson M, Slater GE (1986) Hyperbaric oxygenation and erythrocyte antioxidant enzymes in multiple sclerosis patients. Acta Neu Scand 74: 156-160
5. Arnold G, Holtzman E (1978) Microperoxisomes in the central nervous system of the postnatal rat. Brain Res 155: 1-17
6. Aschner M (1996) The functional significance of brain metallothioneins. FASEB J 10: 1129-1136
7. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ (1998) Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J Neurosci 18: 6241-6264
8. Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Splitsin SV, Fu ZF, Tawadros R, Koprowski H (1995) Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 92: 12041-12045
9. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI (1991) The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain 114: 1271-1280
10. Bast A, Haenen GRMM, Doelman CJA (1991) Oxidants and antioxidants: State of the art. Am J Med 91: 2S-13S
11. Beckman JS, Chen J, Crow JP, Ye YZ (1994) Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 103: 371-380
12. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-C1437
13. Bhat NR, Zhang P, Lee JC, Hogan EL (1998) Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 18: 1633-1641
14. Billiar TR (1995) Nitric oxide. Novel biology with clinical relevance. Ann Surg 222: 339-349
15. Blauwgeers HG, Sillevis SP, de Jong JM, Troost D (1993) Distribution of metallothionein in the human central nervous system. Glia 8: 62-70
16. Blaauwgeers HG, Sillevis SP, de Jong JM, Troost D (1994) Localization of metallothionein in the mammalian central nervous system. Biological Signals 3: 181-187

17. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, Hanley D, Trapp BD (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36: 778-786

18. Boje KM, Arora PK (1992) Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 587: 250-256

19. Bolanos JP, Almeida A, Stewart V, Peuchen S, Land JM, Clark JB, Heales SJR (1997) Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases. J Neurochem 68: 2227-2240

20. Bolanos JP, Heales SJ, Peuchen S, Barker JE, Land JM, Clark JB (1996) Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med 21: 995-1001

21. Bolanos JP, Peuchen S, Heales SJ, Land JM, Clark JB (1994) Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem 63: 910-916

22. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA (1994) Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368: 850-853

23. Bondy SC, LeBel CP (1993) The relationship between excitotoxicity and oxidative stress in the central nervous system. Free Radic Biol Med 14: 633-642

24. Bongarzone ER, Pasquini JM, Soto EF (1995) Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J Neurosci Res 41: 213-221

25. Bongarzone ER, Soto EF, Pasquini JM (1995) Increased susceptibility to degradation by trypsin and subtilisin of in vitro peroxidized myelin proteins. Neurochem Res 20: 421-426

26. Borgerding RA, Murphy S (1995) Induction of conducive nitric oxide synthase in cerebral endothelial cells is regulated by cytokine-activated astrocytes. J Neurochem 65: 1342-1347

27. Boullere AI, Petry KG, Meynard M, Geffard M (1995) Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol 60: 117-124

28. Bowern N, Ramshaw IA, Clark IA, Doherty PC (1984) Inhibition of autoimmun neuropathological process by treatment with an iron-chelating agent. J Exp Med 156: 1532-1543

29. Brenneisen P, Briviba K, Wlaschek M, Wenk J, Scharfetter-Kochanek K (1997) Hydrogen peroxide (H$_2$O$_2$) increases the steady-state mRNA levels of collag enase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med 22: 515-524

30. Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH, Steinman L (1987) Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol 158: 2940-2946

31. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, Lee SC (1994) Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16: 152-161

32. Brown GC, Bolanos JP, Heales SJ, Clark JB (1995) Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 193: 201-204

33. Bruck W, Schmied M, Suchanek G, Bruck Y, Breitschopf H, Poser S, Lassmann H (1994) Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 35: 65-73

34. Burkart V, Gross-Eick A, Bellmann K, Radons J, Kolb H (1995) Suppression of nitric oxide toxicity in islet cells by alpha-tocopherol. FEBS Letters 364: 259-263

35. Calabrese V, Raffaele R, Cosentino E, Rizza V (1995) Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Intern J Clin Pharm Res 14: 119-123

36. Cannella B, Raine CS (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435

37. Caspary EA, Sewell F, Field EJ (1967) Red blood cell fragility in multiple sclerosis. Br Med J 2: 610-611

38. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E (1995) Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201: 223-226

39. Chiamvimovrat N, O’Rourke B, Kamp TJ, Kallen RG, Hofmann F, Flockerzi V, Marban E (1995) Functional consequences of sulfhydryl modification in the pore-forming subunits of cardiovascular Ca$_2^+$ and Na$_+$ channels. Circ Res 76: 325-334

40. Choo L-P, Jackson M, Halliday WC, Mantsch HH (1993) Infrared spectroscopic characterisation of multiple sclerosis plaques in the human central nervous system. Biochim Biophys Acta 182: 333-337

41. Clancy RM, Leszczynska-Piziak J, Abramson SB (1992) Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 90: 1116-1121

42. Colasanti M, Persichini T, Di Pucchio T, Gremo F, Lauro E (1994) The adhesion molecule and cytokine profile of multiple sclerosis lesions. J Neuroimmunol 5: 491-503

43. Colton CA (1995) Induction of nitric oxide in cultured microglia: evidence for a cytoprotective role. Adv Neuroimmunol 5: 491-503

44. Colton CA, Jia M, Li MX, Gilbert DL (1994) K+ modulation of microglial superoxide production: Involvement of voltage-gated Ca$^{2+}$ channels. Am J Physiol 266: C1650-C1655
46. Colton CA, Snell J, Chernyshev O, Gilbert DL (1994) Induction of superoxide anion and nitric oxide production in cultured microglia. Ann N Y Acad Sci 738: 54-63

47. Colton CA, Snell J, Chernyshev O, Gilbert DL (1994) Induction of superoxide anion and nitric oxide production in cultured microglia. Ann N Y Acad Sci 738: 54-63

48. Connor JR (1994) Iron acquisition and expression of iron regulatory proteins in the developing brain: Manipulation by ethanol exposure, iron deprivation and cellular dysfunction. Dev Neurosci 16: 233-247

49. Connor JR, Fine RE (1987) Development of transferrin-positive oligodendrocytes in the rat central nervous system. J Neurosci Res 17: 51-59

50. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res 27: 595-611

51. Cooper RL (1997) Multiple sclerosis: an immune legacy? Medical Hypotheses 49: 307-311

52. Corkill DJ, Woolley K, Guard S, Wright A, Galloway WA, Thomas SW, Askew M, Beckett P, Davis MH, Miller K, Stabler G, Gearing A, Wood LM (1995) The effect of a novel inhibitor of tumour necrosis factor a (TNFα) processing, BB-1101 in experimental autoimmune encephalomyelitis. Br J Pharmacol 80: 2560-2564

53. Corradin SB, Buchmuller-Rouiller Y, Mauel J (1991) Phagocytosis enhances murine macrophage activation by interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol 21: 2553-2558

54. Cowden WB, Cullen FA, Staykova MA, Willenborg DO (1998) Nitric oxide is a potential down-regulating molecule in autoimmune disease: inhibition of nitric oxide production renders PVG rats highly susceptible to EAE. J Neuroimmunol 88: 1-8

55. Cross AH, Keeling RM, Goorha S, San M, Rodi C, Wyatt PS, Manning PT, Misko TP (1996) Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 71: 145-153

56. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88: 45-56

57. Cross AH, Manning PT, Stern MK, Misko TP (1997) Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol 80: 121-130

58. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL/J mice. J Clin Invest 93: 2684-2690

59. Crow JP, Beckman JS (1996) The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Adv Exp Med Biol 387: 147-161

60. Dalton T, Pazdernik TL, Wagner J, Samson F, Andrews GK (1995) Temporal-spatial patterns of expression of metallothionein-I and -II and other stress related genes in rat brain after kainic acid-induced seizures. Neurochem Int 27: 59-71

61. Dawson TM, Hung K, Dawson VL, Steiner JP, Snyder SH (1995) Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann Neurol 37: 115-118

62. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, van der Valk P (1997) Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 56: 10-20

63. de Vries HE, Kuiper J, De Boer AG, Van Berkel TJ, Breimer DD (1997) The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 49: 143-155

64. Delanty N, Reilly M, Pratico D, Fitzgerald DJ, Lawson JA, Fitzgerald, GA (1996) 8-Epi PGF(2alpha): Specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Pharmacol 42: 15-19

65. Denham S, Rowland UJ (1992) Inhibition of the reactive proliferation of lymphocytes by activated macrophages: the role of nitric oxide. Clin Exp Immunol 87: 157-162

66. Dhaunsri GS, Singh B, Singh AK, Kirschner DA, Singh I (1993) Thioridazine induces lipid peroxidation in myelin of rat brain. Neuropharmacol 32: 157-167

67. Ding M, Zhang M, Wong JL, Rogers NE, Ignarro LJ, Voskuhi RR (1998) Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 160: 2560-2564

68. Dobashi K, Pahan K, Chahal A, Singh I (1997) Modulation of endogenous antioxidant enzymes by nitric oxide in rat C6 glial cells. J Neurochem 68: 1896-1903

69. Dugas B, Mossalayi MD, Damais C, Kolb JP (1995) Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol Today 16: 574-580

70. Ebadi M, Iversen PL, Hao R, Cerutis DR, Rojas P, Happe HK, Murrin, LC, Pfeiffer RF (1995) Expression and regulation of brain metallothionein. Neurochem Int 27: 1-22

71. Fagni L, Bockaert J (1996) Effects of nitric oxide on glutamate-gated channels and other ionic channels. J Chem Neuroanat 10: 231-240

72. Fenzy-Melody JE, Garrison AE, Brunnert SR, Weidner JR, Shen F, Shelton BA, Mudgett JS (1998) Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J Immunol 160: 2940-2946

73. Fisher M, Levine PH, Weiner BH, Vauurette CH, Natale A, Johnson MH, Hoagasan JJ (1988) Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. Inflammation 12: 123-131

74. Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central nervous system. Ann Rev Physiol 57: 683-706

75. Gerber MR, Connor JR (1989) Do oligodendrocytes mediate iron regulation in the human brain? Ann Neurol 26: 95-98

76. Gijbels K, Galaray RE, Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 94: 2177-2182
77. Gibbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G (1993) Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 36: 432-440
78. Ginsberg MD (1979) Delayed neurological deterioration following hypoxia. Adv Neurol 26: 21-44
79. Ginsberg MD, Hedley-Whyte ET, Richardson EP, Jr. (1976) Hypoxic-ischemic leukoencephalopathy in man. Arch Neurol 33: 5-14
80. Giovannoni G (1998) Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Multiple Sclerosis 4: 27-30
81. Glabinski A, Tawsek NS, Bartosz G (1993) Increased generation of superoxide radicals in the blood of MS patients. Acta Neurol Scand 88: 174-177
82. Gold R, Zielasek J, Kiefer R, Toyka KV, Hartung HP (1996) Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. Cell Immunol 168: 69-77
83. Gopalakrishna R, Zhen HC, Gundimeda U (1993) Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem 268: 27180-27185
84. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S (1993) Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Letters 330: 181-185
85. Graziewicz M, Wink DA, Laval F (1996) Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage. Carcinogenesis 17: 2501-2505
86. Griot C, Burge T, Brigger S, Richard A, Peterhans E, Vandevelde M (1989) Makrophagen bei der zentralnervosen Hundestaupe: Freunde oder Feinde? Schweizer Archiv Tierheilk 131: 351-359
87. Griot C, Burge T, Vandevelde M, Peterhans E (1989) Antibody-induced generation of reactive oxygen radicals by brain macrophages in canine distemper encephalitis: a mechanism for bystander demyelination. Acta Neuropath 78: 396-403
88. Griot C, Vandevelde M, Richard A, Peterhans E, Stockey R (1990) Selective degradation of oligodendrocytes mediated by reactive oxygen species. Free Rad Res Commun 11: 181-193
89. Grzybicki DM, Kwack KB, Perlmans S, Murphy SP (1997) Nitric oxide synthase type II expression by different cell types in MHV-JHM encephalitis suggests distinct roles for nitric oxide in acute versus persistent virus infection. J Neuroimmunol 73: 15-27
90. Guthikonda P, Baker J, Mattson DH (1998) Interferon-beta-1b (IFN-β) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 82: 133-139
91. Gutowski NJ, Pinkham JM, Akamnu D, Chirico S, Murphy RP (1998) Free radicals in inflammatory neurological disease: Increased lipid peroxidation and haptoglobin levels in Guillain-Barré syndrome. Irish J Med Sci 167: 43-46
92. Gutteridge JMC (1986) Iron promoters of the Fenton reaction and lipid peroxidation can be released from haemoglobin by peroxides. FEBS Letters 201: 291-295
93. Guy J, Ellis EA, Mames R, Rao NA (1993) Role of hydrogen peroxide in experimental optic neuritis. A serial quantitative ultrastructural study. Ophthalmic Res 25: 253-264
94. Guy J, McGorray S, Qi X, Fitzsimmons J, Mancuso A, Rao N (1994) Conjugated deroxamine reduces blood-brain barrier disruption in experimental optic neuritis. Ophthalmic Res 26: 310-323
95. Hall ED (1992) Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol 32: S137-S142
96. Hall ED, Travis MA (1988) Inhibition of arachidonic acid-induced vasogenic brain edema by the non-glucocorticoid 21-aminosteroid U74006F. Brain Res 451: 350-352
97. Hall GL, Compston A, Scolding NJ (1997) Beta-interferon and multiple sclerosis. Trends Neurosci 20: 63-67
98. Halliwell B, Gutteridge JMC (1998) Free Radicals in Biology and Medicine. 3rd Edition, Oxford University Press: Oxford
99. Hansen LA, Willenborg DO, Cowden WB (1995) Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the antioxidant, butylated hydroxyanisole. J Neuroimmunol 62: 69-77
100. Hartung H-P, Schafer B, Heininger K, Toyka KV (1988) Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. Ann Neurol 23: 453-460
101. Hattori H, Takeda M, Kudo T, Nishimura T, Hashimoto S (1992) Cumulative white matter changes in the gerbil brain under chronic cerebral hypoperfusion. Acta Neuropath 84: 21-33
102. Hewson AK, Smith T, Leonard JP, Cuzner ML (1995) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170: 607-612
103. Hooper DC, Bagasra O, Marini JC, Zborek A, Ohnishi ST, Kean R, Champion JM, Sarker AB, Bobroksi L, Farber JL, Akaike T, Maeda H, Koprowski H (1997) Prevention of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44: 345-349
104. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Free radicals in inflammatory neurological disease during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 36: 432-440
105. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Delayed neurological deterioration following hypoxia. Adv Neurol 26: 21-44
106. K.J. Smith et al: Reactive Oxygen and Nitrogen Species and Demyelination
107. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. *Proc Natl Acad Sci U S A* 95: 675-680

108. Hu S, Sheng WS, Peterson PK, Chao CC (1995) Differential regulation by cytokines of human astrocyte nitric oxide production. *Glia* 15: 491-494

109. Hua LL, Liu JSH, Brosnan CF, Lee SC (1998) Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: Implications for multiple sclerosis. *Ann Neurol* 43: 384-387

110. Huie RE, Padmaja S (1993) The reaction of no with superoxide. *Free Rad Res Commun* 18: 195-199

111. Hunter MIS, Nlemadim BC, Davidson DLW (1985) Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. *Neurochem Res* 10: 1645-1652

112. Husain J, Juurlink BHJ (1997) Response of glial cells to ischemia: a line by interleukin-1 and heavy metals. *FEBS Letters* 317: 22-26

113. Hunter MIS, Nlemadim BC, Davidson DLW (1985) Suppression of the oxidative burst in murine microglia by nitric oxide. *Neurosci Lett* 225: 75-78

114. Ikeda M, Sato I, Matsunaga T, Takahashi M, Yuasa T, Hutter C (1993) On the causes of multiple sclerosis. *Medical Hypotheses* 41: 93-96

115. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith J (1993) Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barre syndrome. *Intern Med* 34: 734-737

116. Ischiropoulos H, Zhu L, Chen J, Tsai M, Martin JC, Smith J (1993) Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barre syndrome. *Intern Med* 34: 734-737

117. Jaworowicz DJ, Korytko PJ, Lakhman SS, Boje KMK (1999) Nitric oxide and prostaglandin E2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. *Brain Res Bull* 46: 541-546

118. Jensen GE, Clausen J (1986) Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis - effects of antioxidant supplementation. *Acta Pharmacol Toxicol* (suppl 7) 59: 450-453

119. Johnson AW, Land JM, Thompson EJ, Bolanos JP, Clark JB, Heales SJ (1995) Evidence for increased nitric oxide production in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 58: 107-107

120. Juurlink BHJ (1997) Response of glial cells to ischemia: Roles of reactive oxygen species and glutathione. *Neurosci Biobehav Rev* 21: 151-166

121. Juurlink BHJ, Thorburn SK, Hertz L (1998) Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. *Glia* 22: 371-378

122. Kapoor R, Li YG, Smith KJ (1997) Slow sodium-dependent potential oscillations contribute to ectopic firing in mammalian demyelinated axons. *Brain* 120: 647-652

123. Kikuchi Y, Irie M, Kasahara T, Sawada J, Terao T (1993) Induction of metallothionein in a human astrocytoma cell line by interleukin-1 and heavy metals. *FEBS Letters* 317: 22-26

124. Kim YS, Kim SU (1991) Oligodendroglial cell death induced by oxygen radicals and its protection by catalase. *J Neurosci Res* 29: 100-106

125. Kindwall EP, McQuillen MP, Khatri BO, Gruchow HW, Kindwall ML (1991) Treatment of multiple sclerosis with hyperbaric oxygen. Results of a national registry. *Arch Neurol* 48: 195-199

126. Kiprianova I, Schwab S, Fandrey J, Spranger M (1997) Amino acid concentrations in cerebrospinal fluid of patients with multiple sclerosis. *Acta Neuropathol* 95: 96-98

127. Klockner N, Cellerino A, Bahr M (1998) Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells *In vivo*. *J Neurosci* 18: 1038-1046

128. Klivenyi P, Kekesi K, Juhasz G, Vecsei L (1997) Endogenous nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A* 90: 3024-3027

129. Konat GW, Wiggins RC (1985) Effect of reactive oxygen species on myelin membrane proteins. *J Neurochem* 45: 1113-1118

130. Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, Dietzschold B (1993) In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. *Proc Natl Acad Sci U S A* 90: 3024-3027

131. Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A* 88: 4651-4655

132. Langemann H, Kabiersch A, Newcombe J (1992) Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. *Eur Neurol* 32: 248-252

133. LeVine SM (1997) Iron deposits in multiple sclerosis and Alzheimer's disease brains. *Brain Res* 760: 298-303

134. LeVine SM, Wetzel DL (1998) Chemical analysis of multiple sclerosis lesions by FT-IR microspectroscopy. *Free Radic Biol Med* 25: 33-41

135. Li Z, Chapleau MW, Bates JN, Bielefeldt K, Lee H-C, Abboud FM (1998) Nitric oxide as an autocrine regulator of sodium currents in baroreceptor neurons. *Neuron* 20: 1039-1049

136. Lin RF, Lin TS, Tilton RG, Cross AH (1993) Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. *J Exp Med* 178: 643-648

137. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H (1994) Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. *Ann Neurol* 36: 379-386
138. Liu J, Zhao ML, Brosnan CF, Lee SC (1996) Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1beta and IL-1 receptor antagonist. J Immunol 157: 3569-3576

139. MacEvilly CJ, Muller DFR (1996) Lipid peroxidation in neural tissues and fractions from vitamin E-deficient rats. Free Radic Biol Med 20: 639-648

140. Maeda H, Okamoto T, Akaie T (1998) Human matrix metalloprotease activation by insults of bacterial infection involving proteases and free radicals. Biol Chem 379: 193-200

141. Malfroy B, Doctrow SR, Orr PL, Tocco G, Fedoseyeva EV, Benichou G (1997) Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 177: 62-68

142. Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, Masse B, Kroemer G (1996) Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol 157: 4830-4836

143. Matsuda T, Bates JN, Lewis SJ, Abboud FM, Chapleau M (1997) Inducible nitric oxide synthase and nitric oxide. J Neurochem Res 48: 372-384

144. Mayer M, Noble M (1994) N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 91: 7496-7500

145. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE (1994) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151: 2132-2141

146. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR, Hofman FM (1992) Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci U S A 89: 574-578

147. Merrill JE, Murphy SP (1997) Inflammatory events at the blood brain barrier: Regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav Immun 11: 245-263

148. Merrill JE, Murphy SP, Mitrovic B, MacKenzie-Graham A, Dopp JC, Ding M, Griscavage J, Ignarro LJ, Lowenstein CJ (1997) Inducible nitric oxide synthase and nitric oxide production by oligodendrocytes. J Neurosci Res 48: 372-384

149. Merrill JE, Strom SR, Ellison GW, Myers LW (1989) In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol 9: 84-96

150. Mickel HS, Kempski O, Feuerstein G, Parisi JE, Webster H deF (1990) Prominent white matter lesions develop in Mongolian gerbils treated with 100% normobaric oxygen after global brain ischemia. Acta Neuropath 79: 465-472

151. Minghetti L, Levi G (1998) Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Prog Neurobiol 54: 99-125

152. Minghetti L, Nicoli M, Polazzi E, Creminon C, Maclouf J, Levi G (1997) Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 19: 152-160

153. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, Merrill JE (1994) Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary giall cells in vitro. Neuroscience 61: 575-585

154. Mitrovic B, Ignarro LJ, Vinters HV, Akers M-A, Schmid I, Uttenbogaart C, Merrill JE (1995) Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience 65: 531-539

155. Mollace V, Colasanti M, Rodino P, Massoud R, Lauro GM, Nisticò G (1993) Cytokine-induced nitric oxide generation by cultured astrocytoma cells involves Ca++-calmodulin-independent NO-synthase. Biochem Biophys Res Commun 191: 327-334

156. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225-237

157. Mosley K, Cuzner ML (1996) Receptor-mediated phagocytosis of myelin by macrophages and microglia: effect of opsonization and receptor blocking agents. Neurochem Res 21: 481-487

158. Naidoo R, Knapp ML (1992) Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 38: 2449-2454

159. Nakajima K, Suzuki K (1995) Immunochemical detection of metallothionein in brain. Neurochem Int 27: 73-87

160. Nakajima K, Suzuki K, Otaki N, Kimura M (1991) Detection of metallothionein in brain. Meth Enzymol 205: 387-395

161. Nathan C, Xie Q-W (1994) Regulation of biosynthesis of nitric oxide. J Biol Chem 269: 13725-13728

162. Navikas V, He B, Link J, Haglund M, Soderstrom M, Fredrikson S, Ljungdahl A, Hojeberg J, Qiao J, Olsson T, Link H (1996) Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 119: 213-223

163. Neal JW, Singhrao SK, Jasani B, Newman GR (1996) Immunocytochemically detectable metallothionein is expressed by astrocytes in the ischaemic human brain. Neuropathol Appl Neurobiol 22: 243-247

164. Newcombe J, Li H, Cuzner ML (1994) Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: Implications for pathogenesis. Neuropathol Appl Neurobiol 20: 152-162

165. Noble PG, Antel JP, Yong VW (1994) Astrocytes and cathepsin D in the toxicity of catecholamines to oligodendrocytes. Brain Res 633: 83-90

166. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ (1993) Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci 13: 1441-1453

167. Okuda Y, Nakatsuji Y, Fujimura H, Esumi H, Ogura T, Yanagihara T, Sakoda S (1995) Expression of the inducible isozyme of nitric oxide synthase in the central nervous system of mice correlates with the severity of actively induced experimental allergic encephalomyelitis. J Neuroimmunol 62: 103-112

88

K.J. Smith et al: Reactive Oxygen and Nitrogen Species and Demyelination
168. Oswalde IP, Wynn TA, Sher A, James SL (1992) Interleukin-10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon-gamma-induced activation. *Proc Natl Acad Sci U S A* 89: 8676-8680

169. Owens MW, Milligan SA, Jourdeheil D, Grisham MB (1997) Effects of reactive metabolites of oxygen and nitrogen on gelatinase A activity. *Am J Physiol* 273: L445-L450

170. Park SK, Lin HL, Murphy S (1994) Nitric oxide limits transcriptional induction of nitric oxide synthase in CNS glial cells. *Biochem Biophys Res Commun* 201: 762-768

171. Parkinson JF, Miliric B, Merrill JE (1997) The role of nitric oxide in multiple sclerosis. *Prog Neurobiol* 52: 174-186

172. Pedchenko TV, LeVine SM (1998) Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. *J Neuroimmunol* 84: 188-197

173. Pechen S, Bolanos JP, Heales SJJ, Almeida A, Duchen MR, Clark JB (1997) Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. *Prog Neurobiol* 52: 261-281

174. Piantadosi CA, Tatro L, Zhang J (1995) Hydroxyl radical production in the brain after CO hypoxia in rats. *Free Radic Biol Med* 18: 603-609

175. Pintoaues E, Perraut M, Tholey G (1998) Distribution of mitochondrial manganese superoxide dismutase among rat glial cells in culture. *Glia* 22: 408-414

176. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES (1993) Multiple sclerosis: remyelination of nascent lesions. *Ann Neurol* 33: 137-151

177. Prineas JW, Connell F (1979) Remyelination in multiple sclerosis. *Proc Natl Acad Sci U S A* 89: 8676-8680

178. Qureshi GA, Baig SM (1993) Role of neurotransmitter amino acids in multiple sclerosis in exacerbation, remission and chronic progressive course. *Biogenic Amines* 10: 39-48

179. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. *Arch Biochem Biophys* 288: 481-487

180. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite oxidation of sulfhydrils: The cytotoxic potential of superoxide and nitric oxide. *J Biol Chem* 266: 4244-4250

181. Rainie CS, Wu E (1993) Multiple sclerosis: remyelination in acute lesions. *J Neuropathol Exp Neurol* 52: 199-204

182. Reeder AT, Thapar M, Sapugay AM, Jensen MA (1998) Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. *J Neuroimmunol* 54: 117-127

183. Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. *Brain* 120: 2149-2157

184. Redford EJ, Smith KJ, Gregson NA, Davies M, Hughes P, Gearing AJ, Miller K, Hughes RA (1997) A combined inhibitor of matrix metalloproteinaise activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. *Brain* 120: 1895-1905

185. Reilly MR, Barry P, Lawson JA, Fitzgerald G (1997) Urinary 8-EPGF(1-24): An index of oxidant stress in vivo. *Fibrinolysis Proteinolyis* 11: 81-84

186. Rice-Evans CA (1994) Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: *Free radical damage and its control*, Rice-Evans CA, Burdon R H (eds.), pp. 131-153, Elsevier Science: Amsterdam

187. Robb SJ, Connor JR (1998) An in vitro model for analysis of oxidative death in primary mouse astrocytes. *Brain Res* 788: 125-132

188. Romero FJ (1996) Antioxidants in peripheral nerve. *Free Radic Biol Med* 20: 925-932

189. Rose JW, Hill KE, Wada Y, Kurtz CIB, Tsunoda I, Fujinami RS, Cross, AH (1998) Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Thelier’s virus infection. *J Neuroimmunol* 81: 82-89

190. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA (1994) Nitric oxide regulates production of superoxide and peroxynitrite-dependent lipid per-oxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. *J Biol Chem* 269: 26066-26075

191. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert, JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam J, Simonian, NA, Campion MK, Bartoszak DM, Boudette DN, Braiman J, Brownfield, CM, Coats ME, Cohan LS, Dougherty DS, Kinkel RP, Mass MK, Munschauer, FE, Priore RL, Whitham RH (1997) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Neural 49: 358-363

192. Ruuls SR, Bauer J, Sontrop K, Hultinga I, Hart BA, Dijkstra CD (1995) Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. *J Neuroimmunol* 56: 207-217

193. Ruuls SR, Van Der Linden S, Sontrop K, Hultinga I, Dijkstra CD (1996) Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. *Clin Exp Immunol* 103: 467-474

194. Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. *J Neurochem* 61: 1672-1676

195. Sahrbacher UC, Lechner F, Eugster H-P, Frei K, Lassmann H, Fontana A (1998) Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. *Eur J Immunol* 28: 1330-1336

196. Sankarapandi S, Zweier JL, Mukherjee G, Quinn MT, Huso, DL (1998) Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. *Arch Biochem Biophys* 353: 312-321

197. Sarchielli P, Orlocchio A, Vicinanza F, Pelliccioli GP, Tognoloni M, Saccardi C, Gallai V (1997) Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. *J Neuroimmunol* 80: 76-86
216. Stadler J, Billiar TR, Curran RD, Stuehr DJ, Ochoa JB, Simmons RL (1991) Effect of exogenous and endoge- nous nitric oxide on mitochondrial respiration of rat hepatocytes. Am J Physiol 260: C910-C916

217. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J (1992) S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 89: 444-448

218. Stewart VC, Giovannoni G, Land JM, McDonald WI, Clark JB, Heales SJ (1997) Pretreatment of astrocytes with interferon-alpha/beta impairs interferon-gamma induction of nitric oxide synthase. J Neurochem 68: 2547-2551

219. Stewart VC, Land JM, Clark JB, Heales SJ (1998) Pretreatment of astrocytes with interferon-alpha/beta pre- vents neuronal mitochondrial respiratory chain damage. J Neurochem 70: 432-434

220. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP (1993) Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 45: 175-182

221. Stover JF, Pleines UE, Morganti-Kossmann MC, Kossmann T, Lowitzsch K, Kempski OS (1997) Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 27: 1038-1043

222. Sugaya K, Chouinard M, McKinney M (1997) Immunostimulation protects microglial cells from nitric oxide-mediated apoptosis. Neuroreport 8: 2241-2245

223. Sun N, Grzybicki D, Castro RF, Murphy S, Perlman S (1995) Activation of astrocytes in the spinal cord of mice chronically infected with a neurotropic coronavirus. Virology 213: 482-493

224. Szabo C (1996) Physiological and pathophysiological roles of nitric oxide in the central nervous system. J Neurochem 63: 266-270

225. Szabo C (1996) DNA strandbreakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway trig- gered by peroxynitrite. Free Radic Biol Med 21: 855-869

226. Thom SR (1990) Carbon monoxide-mediated brain lipid peroxidation in the rat. J Appl Physiol 68: 997-1003

227. Thorburne SK, Juurink BHJ (1996) Low glutathione and high iron govern the susceptibility of oligodendroglial pre- cursors to oxidative stress. J Neurochem 67: 1014-1022
261. Zhao W, Tilton RG, Corbett JA, McDaniel ML, Misko TP, Williamson JR, Cross AH, Hickey WF (1996) Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J Neuroimmunol 64: 123-133

262. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP (1995) Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 58: 81-88

263. Zielasek J, Reichmann H, Kunzig H, Jung S, Hartung HP, Toyka KV (1995) Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat. Neurosci Lett 184: 129-132

264. Zielasek J, Tausch M, Toyka KV, Hartung HP (1992) Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol 141: 111-120